Yüklüyor......
Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil
Heart failure continues to be a major global health problem with a pronounced impact on morbidity and mortality and very limited drug treatment options especially with regard to inotropic therapy. Omecamtiv mecarbil is a first-in-class cardiac myosin activator, which increases the proportion of myos...
Kaydedildi:
| Yayımlandı: | Drugs Context |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioExcel Publishing Ltd
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5916097/ https://ncbi.nlm.nih.gov/pubmed/29707029 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212518 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|